Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Appl Immunohistochem Mol Morphol
Main Authors: Cheung, Carol C., Barnes, Penny, Bigras, Gilbert, Boerner, Scott, Butany, Jagdish, Calabrese, Fiorella, Couture, Christian, Deschenes, Jean, El-Zimaity, Hala, Fischer, Gabor, Fiset, Pierre O., Garratt, John, Geldenhuys, Laurette, Gilks, C. Blake, Ilie, Marius, Ionescu, Diana, Lim, Hyun J., Manning, Lisa, Mansoor, Adnan, Riddell, Robert, Ross, Catherine, Roy-Chowdhuri, Sinchita, Spatz, Alan, Swanson, Paul E., Tron, Victor A., Tsao, Ming-Sound, Wang, Hangjun, Xu, Zhaolin, Torlakovic, Emina E.
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2019
Fag:
Hot Topic
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://ncbi.nlm.nih.gov/pubmed/31584451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000800
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker